/Join_Us.gif)
/Morrison_Foerster.gif)
/Clinical_trial_470_x_80_(new).gif)
Clinical Trials Update provides you with latest news about clinical trials conducted by MVA member companies. The update gives insight to progress in studies, results and possible indications.
Post-exposure Vaccination with IMVAMUNE Protects Against Lethal Poxvirus Infection
10 April - In studies with Bavarian Nordic's new and innovative third-generation smallpox vaccine, IMVAMUNE, scientists from Bavarian Nordic have for the first time demonstrated a therapeutic effect of a smallpox vaccine, days after infection. With the current available first- and second-generation smallpox vaccines no evidence of a therapeutic effect has ever been shown in animal models. This discovery was recently published in the prestigious Journal of Clinical investigation.
IMVAMUNE is currently in phase two clinical studies.
